Avidity Partners Management LP
Avidity Partners Management LP reported 45 US-listed holdings worth $624.4 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Dianthus Therapeutics Inc. (32.8%), CG Oncology Inc. (15.9%) and Oruka Therapeutics Inc. (11.6%). Against the quarter before, it opened 9 positions, added to 4, trimmed 27 and sold out of 16.
Reported holdings$624.4M-33.3% on Q1 2026
Positions45-7 on Q1 2026
The largest ten81.9%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
OpenedAdded toTrimmed
The 14 largest of its 45 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +75.2% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.
Its reported holdingsThe S&P 500
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Opened 9Added 4Held 5Trimmed 27Sold out 16
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 9
- Mobia Med Inc. MOBI$10.7 million
- Immunic Inc. IMUX$10.3 million
- Senseonics Hldgs Inc. Com SENS$9.1 million
- Nuvectis Pharma Inc. NVCT$3.7 million
- Alamar Biosciences Inc. ALMR$3.0 million
- Avalyn Pharma Inc. AVLN$2.0 million
- Kailera Therapeutics Inc. KLRA$1.8 million
- Scynexis Inc. SCYX$1.1 million
and 1 more in the table below
Added to 4
- CG Oncology Inc. CGON+110,000 shares · +9%
- Insulet Corp. PODD+14,000 shares · +140%
- Structure Therapeutics Inc. GPCR+20,000 shares · +26%
- Tempus Ai Inc. TEM+15,000 shares · +17%
Trimmed 27
- Dianthus Therapeutics Inc. DNTH-2.1 million shares · -50%
- Oruka Therapeutics Inc. ORKA-760,424 shares · -50%
- Jade Biosciences Inc. JBIO-1.1 million shares · -39%
- Perspective Therapeutics Inc CATX-5.8 million shares · -48%
- Teva Pharmaceutical Industries Ltd. TEVA-450,100 shares · -69%
- Aktis Oncology Inc. AKTS-452,932 shares · -48%
- Enliven Therapeutics Inc. ELVN-250,000 shares · -31%
- Vir Biotechnology, Inc. VIR-1.1 million shares · -67%
and 19 more in the table below
Sold out of 16
- Immunic Inc. IMUX$13.9 million last quarter
- Humana Inc. HUM$5.9 million last quarter
- Scynexis Inc. SCYX$3.8 million last quarter
- ICON plc ICLR$3.7 million last quarter
- Natera Inc Com NTRA$3.7 million last quarter
- Hims & Hers Health, Inc. HIMS$2.9 million last quarter
- Corcept Therapeutics Inc. CORT$2.6 million last quarter
- Centene Corp. CNC$2.3 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Dianthus Therapeutics Inc. DNTH | 2.1M | $205.1 million | 32.85% | -2.1M |
| CG Oncology Inc. CGON | 1.4M | $99.4 million | 15.92% | +110.0K |
| Oruka Therapeutics Inc. ORKA | 760.4K | $72.4 million | 11.59% | -760.4K |
| Jade Biosciences Inc. JBIO | 1.7M | $37.8 million | 6.05% | -1.1M |
| Enliven Therapeutics Inc. ELVN | 550.0K | $27.9 million | 4.47% | -250.0K |
| Perspective Therapeutics Inc CATX | 6.3M | $21.5 million | 3.44% | -5.8M |
| Aktis Oncology Inc. AKTS | 484.2K | $15.6 million | 2.50% | -452.9K |
| Palvella Therapeutics Inc. Ne PVLA | 70.0K | $10.7 million | 1.71% | -70.0K |
| Mobia Med Inc. MOBI | 798.3K | $10.7 million | 1.71% | new |
| Repligen Corp. RGEN | 77.8K | $10.6 million | 1.70% | -77.8K |
| Immunic Inc. IMUX | 669.9K | $10.3 million | 1.65% | new |
| Senseonics Hldgs Inc. Com SENS | 1.6M | $9.1 million | 1.46% | new |
| Karyopharm Therapeutics Inc. KPTI | 924.5K | $9.0 million | 1.45% | -3.0K |
| Teva Pharmaceutical Industries Ltd. TEVA | 200.0K | $6.8 million | 1.09% | -450.1K |
| Dexcom Inc. DXCM | 100.0K | $6.7 million | 1.08% | -90.0K |
| Tempus Ai Inc. TEM | 105.0K | $6.1 million | 0.97% | +15.0K |
| Medtronic plc MDT | 70.0K | $5.5 million | 0.88% | -130.0K |
| Vir Biotechnology, Inc. VIR | 519.3K | $5.3 million | 0.85% | -1.1M |
| Structure Therapeutics Inc. GPCR | 98.0K | $5.3 million | 0.84% | +20.0K |
| Encompass Health Corp. EHC | 42.0K | $4.2 million | 0.68% | -42.0K |
| Tenax Therapeutics Inc. TENX | 265.9K | $3.9 million | 0.62% | -215.9K |
| Nuvectis Pharma Inc. NVCT | 200.0K | $3.7 million | 0.59% | new |
| Insulet Corp. PODD | 24.0K | $3.7 million | 0.59% | +14.0K |
| Boston Scientific Corp. BSX | 80.0K | $3.4 million | 0.55% | -40.0K |
| Satellos Bioscience Inc. MSLE | 387.8K | $3.0 million | 0.48% | -387.8K |
| Alamar Biosciences Inc. ALMR | 110.0K | $3.0 million | 0.48% | new |
| Context Therapeutics Inc. CNTX | 5.0M | $2.8 million | 0.44% | -5.0M |
| Gilead Sciences, Inc. GILD | 20.0K | $2.5 million | 0.40% | -20.0K |
| Charles River Laboratories International, Inc. CRL | 10.0K | $2.3 million | 0.36% | no change |
| Phathom Pharmaceuticals Inc. PHAT | 200.0K | $2.2 million | 0.35% | -298.8K |
| Avalyn Pharma Inc. AVLN | 60.0K | $2.0 million | 0.32% | new |
| Kailera Therapeutics Inc. KLRA | 80.0K | $1.8 million | 0.28% | new |
| Genmab A/S GMAB | 50.0K | $1.4 million | 0.22% | -50.0K |
| Intellia Therapeutics Inc. NTLA | 75.0K | $1.3 million | 0.20% | -75.0K |
| Corvus Pharmaceuticals Inc. CRVS | 80.0K | $1.2 million | 0.19% | -150.0K |
| Oddity Tech Ltd ODD | 70.0K | $1.1 million | 0.17% | -70.0K |
| Scynexis Inc. SCYX | 260.2K | $1.1 million | 0.17% | new |
| Evommune Inc. EVMN | 75.0K | $996,750 | 0.16% | new |
| Abbott Laboratories ABT | 10.0K | $907,400 | 0.15% | no change |
| Bridgebio Pharma Inc. BBIO | 10.0K | $744,800 | 0.12% | no change |
| Peloton Interactive, Inc. PTON | 100.0K | $591,000 | 0.09% | -300.0K |
| Legend Biotech Corp. LEGN | 15.0K | $433,200 | 0.07% | no change |
| Bridgebio Oncology Therapeutics Ord BBOT | 43.9K | $334,160 | 0.05% | -43.9K |
| Savara Inc. SVRA | 50.0K | $308,000 | 0.05% | no change |
| Trevi Therapeutics Inc. TRVI | 6.7K | $124,209 | 0.02% | -6.7K |
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.